Eglumegad is primarily investigated for its potential therapeutic applications in neurological and psychiatric disorders. It acts as a selective agonist for the metabotropic glutamate receptor subtype 2 (mGluR2), which plays a role in modulating neurotransmitter release and synaptic plasticity. Research focuses on its use in treating conditions such as anxiety, schizophrenia, and addiction, as it may help regulate glutamate signaling imbalances associated with these disorders. Additionally, it has been explored for its neuroprotective properties, potentially aiding in conditions like Parkinson's disease or epilepsy. Clinical studies are ongoing to evaluate its efficacy and safety in these applications.